Trial Profile
A Randomized, Open Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigators Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Who Are Current or Former Smokers
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Veliparib (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie; AbbVie Germany
- 18 Mar 2020 Status changed from active, no longer recruiting to completed.
- 13 Mar 2020 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 05 Mar 2020 This trial has been completed in Hungary, according to European Clinical Trials Database record.